Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
entecavir + tenofovir alafenamide + tenofovir disoproxil fumarate + tenofovir amibufenamide + peginterferon alfa
- Development stage
- Unknown
- Lead developer
- Huashan Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination therapeutic regimen consists of four nucleos(t)ide analogues (entecavir, tenofovir alafenamide, tenofovir disoproxil fumarate, and tenofovir amibufenamide) and peginterferon alfa. It is being evaluated in the REASON study, a multicenter observational study led by Huashan Hospital in China, for the treatment of chronic hepatitis B (CHB). The regimen combines potent viral suppression via multiple polymerase inhibitors with the immunomodulatory effects of interferon to optimize treatment outcomes, particularly in patients who are treatment-naive or have had partial responses to first-line therapies. Tenofovir amibufenamide (TMF) is a novel tenofovir prodrug developed in China by Hansoh Pharma that offers improved plasma stability and targeted delivery to the liver compared to older tenofovir formulations.
- Other names
- entecavir + tenofovir alafenamide + tenofovir disoproxil fumarate + TMF + interferonETV + TAF + TDF + TMF + IFN
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)HBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on entecavir + tenofovir alafenamide + tenofovir disoproxil fumarate + tenofovir amibufenamide + peginterferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on entecavir + tenofovir alafenamide + tenofovir disoproxil fumarate + tenofovir amibufenamide + peginterferon alfa.